UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/591,847	01/09/2007	Kenneth Hofland	BJS-620-454	3278
23117 NIXON & VAN	7590 10/13/201 NDERHYE, PC	EXAMINER		
901 NORTH GLEBE ROAD, 11TH FLOOR			KRISHNAN, GANAPATHY	
ARLINGTON, VA 22203			ART UNIT	PAPER NUMBER
			1623	
			MAIL DATE	DELIVERY MODE
			10/13/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
Examiner-Initiated Interview Summary	10/591,847	HOFLAND ET AL.
Examiner-initiated interview Summary	Examiner	Art Unit
	Ganapathy Krishnan	1623
All Participants:	Status of Application:	<u> </u>
(1) <u>Ganapathy Krishnan</u> .	(3)	
(2) Mr. B.J. Sadoff.	(4)	
Date of Interview: 6 October 2010	Time:	
Type of Interview: ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant Exhibit Shown or Demonstrated: ☐ Yes If Yes, provide a brief description:	nt's representative)	
Part I.		
Rejection(s) discussed: None		
Claims discussed: 1-4 and 6-10		
Prior art documents discussed: None		
Part II.		
SUBSTANCE OF INTERVIEW DESCRIBING THE GENER see continuation sheet	RAL NATURE OF WHAT WAS	S DISCUSSED:
Part III.		
 ☐ It is not necessary for applicant to provide a separate redirectly resulted in the allowance of the application. The of the interview in the Notice of Allowability. ☐ It is not necessary for applicant to provide a separate redid not result in resolution of all issues. A brief summary 	e examiner will provide a writte ecord of the substance of the	en summary of the substance interview, since the interview
Comments V - V con		
/Ganapathy Krishnan/ Examiner, Art Unit 1623		
	pplicant/Applicant's Representat	ive Signature – if appropriate)

U.S. Patent and Trademark Office PTOL-413B (04-03) The Examiner informed the Attorney of record that:

- 1. Cancel claims 6-10 since they are not tangible composition claims since the recited active agents cannot be made as a composition with radiation as one of the components.
- 2. In claim 1:
- a) replace the terms, "which comprises" with "in the brain comprising".
- b) at line 3, replace the term "topoisomerase-II poison" with "etoposide" or recite etoposide along with the other specific topoisomerase-II poisons recited at page 8, lines 14-18 using Markush language.
- c) at line 3, instead of "bis-dioxypiperazine" recite the specific dioxypiperazine, namely dexrazoxane, recited in claim 3 and cancel claim 3.
- d) at line 3, replace the term "wherein" with "and"
- e) recite the dosage levels (stated at pages 9-10 of the specification) of all the active agents in claim 1 including the radiation.

The above amendments will put the application in a condition for allowance.

Mr. Sadoff said he will get back to the Examiner after talking to the inventors.